lamyropsis/抗真菌藥

To date, there are no drugs or other therapeutics approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19 that has spread globally resulting in the ongoing pandemic as declared by the World Health Organization (WHO) on 11 March 2020. While the majority of patients have

Tumor heterogeneity leads to a significant difference in the rate of response to drugs in patients with the same pathological type. According to the information, the current initial effective rate of domestic and foreign chemotherapeutic single drug is no more than 30%, even if treated with repeated

This is an open-label single-dose study. Approximately 40 total subjects will be enrolled. In each of the 3 hepatic impairment groups (mild hepatic dysfunction [Child-Pugh score of 5 - 6], moderate hepatic dysfunction [Child-Pugh score of 7 - 9], severe hepatic dysfunction [Child Pugh score of 10 -

This study will look for possible protective effects silymarin on kidney injury in patients receiving cisplatin.

Prostate cancer is the most common invasive malignancy and the second leading cause of cancer death in American males. In 2005, an estimated 230,000 men will be diagnosed and 30,000 will die from prostate cancer. The current estimated risk of developing prostate cancer is 1 in 6 men. Carcinogenesis

BIOAVAILABILTY STUDY: 1. Clinical Protocol Screening/Informed Consent: Sixteen subjects will be recruited for the clinical protocol. All protocols, consent forms, and HIPAA forms shall be IRB-approved prior to initiating any study procedure or recruitment. At a screening/informed consent visit, the

Background: IBS (Irritable Bowel Syndrome) is a disorder of motility of the entire GI tract that produces cramping, abdominal pain, constipation, and/or diarrhea and sometimes passing of mucus in bowel movements. In most people with IBS, the GI tract is highly sensitive to many stimuli, including

The objective of this exploratory project is to assess the feasibility of investigating the effect of silymarin, derived from the milk thistle plant, Silybum marianum, in preventing and reversing the complications of chronic infection with HCV and/or clearing HCV infections, thereby generating